| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(11)61219-1 |
| P8608 | Fatcat ID | release_h7vgcv3p5ze63eoppigf5shk2i |
| P698 | PubMed publication ID | 21856480 |
| P50 | author | John R Teerlink | Q90422543 |
| P2093 | author name string | Andrew A Wolff | |
| Nelson B Schiller | |||
| Fady I Malik | |||
| Khalil G Saikali | |||
| Jacqueline H Lee | |||
| Michael M Chen | |||
| Jonathan H Goldman | |||
| Rafael D Escandon | |||
| Mohammad Reza Habibzadeh | |||
| Rachel Bee | |||
| Cyril P Clarke | |||
| Lyndsey Elliott | |||
| P2860 | cites work | Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond | Q24645066 |
| Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial | Q28300233 | ||
| Cardiac myosin activation: a potential therapeutic approach for systolic heart failure | Q30583292 | ||
| Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure | Q34117227 | ||
| The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. | Q34209536 | ||
| A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators | Q34483643 | ||
| ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology | Q34830023 | ||
| Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. | Q36357779 | ||
| Assessment of left ventricular function by cardiac ultrasound. | Q36656775 | ||
| Effects of cardiac myosin isoform variation on myofilament function and crossbridge kinetics in transgenic rabbits | Q37382700 | ||
| A novel approach to improve cardiac performance: cardiac myosin activators | Q37398701 | ||
| Cardiac inotropes: current agents and future directions | Q37851240 | ||
| Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. | Q39155695 | ||
| A critical review of the systolic time intervals | Q41045302 | ||
| Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study | Q44371716 | ||
| Performance of phonoelectrocardiographic left ventricular systolic time intervals and B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction. | Q46327425 | ||
| Confidence interval criteria for assessment of dose proportionality. | Q52069368 | ||
| Executive Summary: Heart Disease and Stroke Statistics—2010 Update | Q57413935 | ||
| The search for the ideal positive inotropic agent | Q70772286 | ||
| Systolic time intervals in heart failure in man | Q72026834 | ||
| P433 | issue | 9792 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systole | Q496359 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 667-675 | |
| P577 | publication date | 2011-08-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study | |
| P478 | volume | 378 |
| Q34995668 | 2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure |
| Q36756838 | AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility. |
| Q39172885 | Actomyosin based contraction: one mechanokinetic model from single molecules to muscle? |
| Q35139964 | Acute decompensated heart failure update |
| Q47137936 | Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil. |
| Q38139089 | Antagonist molecules in the treatment of angina |
| Q57612082 | Biobank-driven genomic discovery yields new insight into atrial fibrillation biology |
| Q26826988 | Calcium sensitizers: What have we learned over the last 25 years? |
| Q38939243 | Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe? |
| Q84799461 | Cardiac myosin activation: will theory and practice coincide? |
| Q55025652 | Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. |
| Q45989354 | Cardiac myosin activators: up and coming. |
| Q34755677 | Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy |
| Q28085736 | Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs |
| Q44655145 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial |
| Q37995246 | Developments in heart failure 2011. |
| Q46143451 | Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction |
| Q92441606 | Direct Sarcomere Modulators Are Promising New Treatments for Cardiomyopathies |
| Q43711626 | Do inotropes really have a future? |
| Q47655251 | Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium |
| Q55286667 | Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats. |
| Q38694200 | Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype? |
| Q38179215 | End-stage heart failure non-pharmacological therapy: recent advances in pacemakers, pressure monitors, pumps and other devices |
| Q27320554 | Ensemble force changes that result from human cardiac myosin mutations and a small-molecule effector |
| Q37363558 | Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments |
| Q26827691 | Force generation by kinesin and myosin cytoskeletal motor proteins |
| Q49907634 | Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes. |
| Q38780801 | From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure |
| Q38182010 | Heart failure highlights in 2012-2013. |
| Q84894462 | Heart failure: Cardiac myosin activator shows promise in phase II trial |
| Q37701056 | Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases |
| Q37258267 | Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program |
| Q38208442 | Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus |
| Q38061473 | Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option? |
| Q97094347 | Inotropic Assessment in Engineered 3D Cardiac Tissues using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in the BiowireTM II Platform |
| Q47965167 | Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. |
| Q43161763 | Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity". |
| Q38734731 | Long-term intravenous inotropes in low-output terminal heart failure? |
| Q90701260 | Lost in translation: Interpreting cardiac muscle mechanics data in clinical practice |
| Q41242943 | Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil |
| Q37920401 | Medical therapy for chronic heart failure |
| Q38998576 | Metabolic support for the heart: complementary therapy for heart failure? |
| Q28255887 | Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes |
| Q36341946 | Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C |
| Q38076688 | Molecular targets of current and prospective heart failure therapies |
| Q94592130 | Multiparametric Mechanistic Profiling of Inotropic Drugs in Adult Human Primary Cardiomyocytes |
| Q39218629 | New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations |
| Q47572193 | New heart failure pharmacotherapy in clinical trials: a hope in progress |
| Q38594785 | New medical therapies for heart failure |
| Q92069739 | New perspective in heart failure management: could myosin activators be the answer? |
| Q38209074 | Novel drug mechanisms in development for heart failure |
| Q38202895 | Novel drug targets in clinical development for heart failure. |
| Q41856322 | Novel strategies for the treatment of heart failure |
| Q46650156 | Omecamtiv Mecarbil Abolishes Length-Mediated Increase in Guinea Pig Cardiac Myofiber Ca2+ Sensitivity |
| Q100305798 | Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC-HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials |
| Q38639973 | Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure |
| Q57316359 | Omecamtiv mecarbil: a promising new drug in systolic heart failure |
| Q47102056 | Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament. |
| Q57494888 | Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure |
| Q97418201 | Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil |
| Q36972415 | Pharmacological Strategies to Retard Cardiovascular Aging |
| Q40964821 | Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure |
| Q57153298 | Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q57822514 | Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure |
| Q36645693 | Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects |
| Q41103151 | Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure |
| Q37418216 | SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope. |
| Q57071192 | Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy |
| Q52816840 | Searching for the perfect agent to improve cardiac contractility. |
| Q38215304 | Serelaxin : a potential new drug for the treatment of acute heart failure |
| Q26825154 | Signaling effectors underlying pathologic growth and remodeling of the heart |
| Q92950627 | Small molecule studies: the fourth wave of muscle research |
| Q89750991 | Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery |
| Q89707757 | Systolic time intervals in patients with heart failure: time to teach new dogs old tricks |
| Q28260629 | Targeting the sarcomere to correct muscle function |
| Q34209536 | The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. |
| Q38870685 | The myosin activator omecamtiv mecarbil: a promising new inotropic agent |
| Q36036237 | The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat |
| Q64232857 | Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations |
| Q33728779 | Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy |
| Q39258163 | Update on the Management of Acute Decompensated Heart Failure |
| Q26774435 | Use of Inotropic Agents in Treatment of Systolic Heart Failure |
| Q38123740 | What's new in the treatment of acute heart failure? |
| Q92588956 | Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials |
Search more.